

primary higher fatty alcohol. The method for reducing serum cholesterol consists of orally administering the composition provided to human subjects.

AMENDMENTS TO THE CLAIMS:

Please delete Claim 36.

Claim 1 (currently amended) A composition for lowering ~~LDL-serum~~ cholesterol levels ~~in human subjects, or elevating HDL cholesterol level in blood of a mammal wherein the said~~ composition comprises one or more ~~esters of poliecosanol, wherein the poliecosanol is selected from the group consisting of eicosanol, heneicosanol, docosanol, tricosanol, tetracosanol, pentacosanol, hexacosanol, heptacosanol, octacosanol, nonacosanol, triacontanol, dotriacontanol, tetratriacontanol and hexatriacontanol~~ primary aliphatic alcohol fatty acid esters, wherein the fatty acids are long chain fatty acids.

Claim 2 (currently amended) The composition according to Claim 1, wherein the fatty acid moiety of the esters is a carboxylic acid containing from 2 to 22 carbon atoms is linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid or docasahexanoic acid.

Claim 3 (currently amended) The composition according to Claim 2, ~~further comprising one or more food substances~~ wherein the primary aliphatic alcohol is eicosanol, docosanol, tricosanol, tetracosanol, hexacosanol, octacosanol or triacontanol.

Claim 4 (currently amended) ~~The~~ A food composition comprising one or more primary aliphatic alcohol fatty acid esters according to Claim 3, in combination with a food substance, wherein the said food substance is selected from the group consisting of ~~table margarine, shortening, mayonnaise, vegetable oil, ice cream, milk and yogurt~~ edible oil, margarine, butter, salad dressing, milk and beverages.

Claim 5 (currently amended) ~~The composition according to Claim 2, further comprising a pharmaceutically acceptable component selected from the group consisting of an A pharmaceutical composition comprising one or more primary aliphatic alcohol fatty acid esters of Claim 3, in combination with a pharmaceutically acceptable carrier, excipient, antioxidant, coloring agent, binder and stabilizer or dilutant.~~

Please add new claims 37 – 39.

62 Claim ~~37~~ (added) The composition according to Claim 1, wherein the primary aliphatic alcohol is eicosanol, docosanol, tricosanol, tetracosanol, hexacosanol, octacosanol or triacontanol.

63 Claim ~~38~~ (added) A food composition comprising one or more primary aliphatic alcohol fatty acid esters according to Claim 2, in combination with a food substance, wherein said food substance is selected from the group consisting of edible oil, margarine, butter, salad dressing, milk and beverages.

64 Claim ~~39~~ (added) A food composition comprising one or more primary aliphatic alcohol fatty acid esters according to Claim 1, in combination with a food substance, wherein said food substance is selected from the group consisting of edible oil, margarine, butter, salad dressing, milk and beverages.

65 Claim ~~40~~ (added) A pharmaceutical composition comprising one or more primary aliphatic alcohol fatty acid esters of Claim 2, in combination with a pharmaceutically acceptable carrier, excipient, or dilutant.

66 Claim 41 (added) A pharmaceutical composition comprising one or more primary aliphatic alcohol fatty acid esters of Claim 1, in combination with a pharmaceutically acceptable carrier, excipient, or dilutant.

67 Claim 42 (added) The composition according to Claim 5 in the form of a capsule, tablet, liquid or powder.

68 Claim 43 (added) A method for lowering serum cholesterol levels in human subjects, which comprises orally administering to the human subjects an effective amount of the composition according to Claim 4.

69 Claim 44 (added) A method for lowering serum cholesterol in human subjects, which comprises orally administering to the human subjects a pharmaceutically effective amount of the composition according to Claim 5.

REMARKS:

The Examiner's Office Action has been reviewed and considered, and revised claims are submitted in light of the Examiner's comments.

Applicant has amended Claims 1-5, deleted Claim 36, and has added new Claims 37- 44. In view of the amendments and the remarks below, Applicant respectfully submits that the cited references do not singularly or in combination anticipate, teach, or suggest the inventions that are the subject of the amended and newly submitted claims.

Anticipation

As stated by the Examiner, Levin et al. discloses compositions containing esters of tetracosanol, hexacosanol, octacosanol, and triacontanol, where the acid residue may be organic or inorganic acid. Levin et al. discloses the use of these esters for reducing anoxia, for